Cytori Therapeutics Inc. (CYTX) Stock Price Down 1.4%
Cytori Therapeutics Inc. (NASDAQ:CYTX) shares were down 1.4% during trading on Wednesday . The stock traded as low as $2.14 and last traded at $2.16, with a volume of 149,626 shares. The stock had previously closed at $2.19.
Several research analysts recently commented on CYTX shares. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Cytori Therapeutics in a research note on Wednesday, July 20th. Zacks Investment Research raised Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Tuesday, July 12th. Finally, Roth Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cytori Therapeutics in a research report on Tuesday, June 28th.
The firm’s market capitalization is $42.42 million. The stock has a 50-day moving average of $2.07 and a 200-day moving average of $2.76.
Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, August 4th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.04. The company earned $1.10 million during the quarter, compared to analyst estimates of $2.50 million. The company’s revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.06) earnings per share. Equities analysts predict that Cytori Therapeutics Inc. will post ($1.48) earnings per share for the current year.
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.